Click here for slides on this topic


t-PA

Abbreviation for tissue plasminogen activator, a serine endopeptidase synthesized by endothelial cells, the major physiologic activator of plasminogen.
The following content matched the glossary term: t-PA

NDEI.org Press Release National Diabetes Awareness Month

Top

NDEI.org Celebrates National Diabetes Awareness Month With New Patient Education Handout on Lifestyle Interventions November 27, 2012: NDEI.org, the official website of The National Diabetes Education Initiative® (NDEI®), announced today the publication of a downloadable patient education handout reviewing lifestyle interventions for managing type 2 diabetes. The handout is the latest in a series of clinical practice tools from NDEI.org aimed at increasing diabetes awareness in observance of National Diabetes Awareness Month during November 2012.

NDEI.org Press Release Interactive Case Study on ADA/EASD Diabetes Treatment Guidelines

Top

NDEI.org Interactive Case Study Explores ADA/EASD Recommendations for Individualized Treatment in Type 2 Diabetes November 15, 2012: NDEI.org, the official website of The National Diabetes Education Initiative® (NDEI®), announced today the launch of an interactive case study exploring the concept of individualized treatment for patients with uncontrolled type 2 diabetes.

NDEI.org Press Release Expert Commentary on Halted Look AHEAD Trial from Anne Peters, MD

Top

Anne Peters, MD, on the Halted Look AHEAD Trial: "Prevention of Obesity and Diabetes Remains Key" NDEI.org expert commentary offers insights on discontinuation of lifestyle intervention trial October 26, 2012: NDEI.org, the official website of The National Diabetes Education Initiative® (NDEI®), published today expert commentary from Anne Peters, MD, on the discontinuation, 2 years premature, of the Look AHEAD (Action for Health in Diabetes) trial, in which lifestyle intervention failed to reduce cardiovascular outcomes among people with type 2 diabetes.

NDEI.org Press Release NDEI Press Release Patient Education Handout Explores Hypertension Control

Top

NDEI.org Patient Education Handout Explores Hypertension Prevalence, Offers Tips for Optimal Control October 18, 2012: NDEI.org, the official website of The National Diabetes Education Initiative® (NDEI®) published a downloadable patient education handout addressing the sobering prevalence of hypertension (high blood pressure) in the United States, now estimated at 66.9 million adults—or 30.4% of the population.

NDEI.org Press Release American Diabetes Association (ADA) Scientific Sessions Coverage

Top

NDEI.org Unveils Coverage Plans for American Diabetes Association sessions. Visit Booth #847 to Enter NDEI.org iPad Raffle May 9, 2012: NDEI.org, the official website of The National Diabetes Education Initiative® (NDEI®), unveiled today its plans to offer comprehensive coverage of the upcoming American Diabetes Association (ADA) 72nd Scientific Sessions. NDEI.org is an online community for healthcare professionals that provides clinically relevant information and skillfully designed programs to address educational and practice gaps in diabetes and improve patient outcomes.

NDEI.org Press Release Vivian Fonseca, MD, on “Futility of Adding Omega-3 Fatty Acids in the Hope of Added Benefit” in the ORIGIN Trial

Top

Vivian Fonseca, MD, on the "Futility of Adding Omega-3 Fatty Acids in the Hope of Added Benefit" in the ORIGIN Trial July 31, 2012: NDEI.org, the official website of The National Diabetes Education Initiative® (NDEI®), published today a webcast on the results of the ORIGIN trial featuring expert commentary from Vivian A. Fonseca, MD. “These results may help us to education our patients on the futility of adding omega-3 fatty acids in the hope of added benefit, in the absence of data supporting their use,” said Dr Fonseca, a Professor of Medicine and Pharmacology, and Chief of the Section of Endocrinology at Tulane University Health Sciences Center in New Orleans, Louisiana.

NDEI.org Press Release Peter Libby, MD, on New JUPITER Analysis: “These Data Put Diabetes Risk from Statin Therapy in Perspective”

Top

Peter Libby, MD, on New JUPITER Analysis: "These Data Put Diabetes Risk from Statin Therapy in Perspective" NDEI.org expert commentary explores statins and diabetes risk September 18, 2012: NDEI.org, the official website of The National Diabetes Education Initiative® (NDEI®) published expert commentary from Peter Libby, MD, on a new analysis of the landmark JUPITER primary prevention trial demonstrating that the cardiovascular and mortality benefits conferred by statin therapy outweigh the risk for developing diabetes among patients at low risk for cardiovascular disease (CVD).

Comparative effectiveness of patient education methods for type 2 diabetes: a randomized controlled trial

Top

Sperl-Hillen J, Beaton S, Fernandes O, Von Worley A, Vazquez-Benitez G, Parker E, Hanson A, Lavin-Tompkins J, Glasrud P, Davis H, Adams K, Parsons W, Spain CV. Comparative effectiveness of patient education methods for type 2 diabetes: a randomized controlled trial. Arch Intern Med. 2011 Oct 10. [Epub ahead of print] Group education for patients with suboptimally controlled diabetes has not been rigorously studied.

Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes

Top

Cohen LB, Taviera TH, Khatana SA, Dooley AG, Pirraglia PA, Wu WC. Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes. Diabetes Educ. 2011 Oct 21. [Epub ahead of print]. To assess whether VA MEDIC-E (Veterans Affairs Multi-disciplinary Education and Diabetes Intervention for Cardiac risk reduction— Extended for 6 months), a pharmacist-led shared medical appointments program, could improve attainment of target goals for hypertension, hyperglycemia, hyperlipidemia, and tobacco use in patients with type 2 diabetes compared to standard primary care after 6 months of intervention.

Clinical Outcomes Using Long-Term Combination Therapy With Insulin Glargine and Exenatide In Patients With Type 2 Diabetes

Top

Levin PA, Mersey JH, Zhou S, Bromberger LA. Clinical Outcomes Using Long-Term Combination Therapy With Insulin Glargine and Exenatide In Patients With Type 2 Diabetes. Endocr Pract. 2011 Jul 8:1-28. [Epub ahead of print] OBJECTIVE: To examine the long-term effects of combination insulin glargine/exenatide treatment on glycemic control.

1 2 3 Next 

Slide Library Results

Search Results for: t-PA Slides Found: 27
Effect of Orlistat on Weight Loss in Patients With Type 2 Diabetes
Effect of Orlistat on Weight Loss in Patients With Type 2 Diabetes
Effect of Orlistat on Lipids and Glycemic Control in Patients
Malabsorptive Surgery: Outcomes
Bariatric Surgery: Gastrorestrictive Procedures
Gastrorestrictive Surgery: Outcomes
Laparoscopy and Liposuction
Pramlintide Adjunctive Therapy Offers Long-Term Glycemic Control
Effect of Pramlintide Adjunctive Therapy on Weight in Patients With Type 2 Diabetes
Secondary Causes of Obesity
Environmental Factors that Promote Obesity
Nonpharmacologic Treatments for Obesity
Bariatric Surgery for Obesity
JNC 8 Guidelines BP Treatment Adults Over 60 PPT | NDEI
JNC 8 Guidelines BP Treatment Goal Adults Under Age 60 PPT | NDEI
BP Treatment Goal for Adults With CKD JNC 8 Guidelines PPT | NDEI
BP Treatment Threshold & Goal in Adults Aged Greater Than or Equal to 18 Years With Diabetes | NDEI
Therapy Initiation & Goals for Blood Pressure | NDEI
JNC 8 Hypertension Treatment Algorithm Guidelines PPT | NDEI
JNC 8 Hypertension Treatment Algorithm Adults With Diabetes or CKD | NDEI
JNC 8 Hypertension Guidelines 2014 PPT | NDEI
JNC 8 Guidelines First-Line Antihypertensive Therapy PPT | NDEI
JNC 8 Guidelines First-Line Antihypertensive Therapy for Black Patients | NDEI
JNC 8 Guidelines Treatment Hypertension CKD PPT | NDEI
Antihypertensive Therapy to Achieve Goal BP JNC 8 PPT | NDEI
Antihypertensive Therapy Dosing Strategies | NDEI
Blood Pressure Targets Type 2 Diabetes AHA ADA Guidelines | NDEI